Skip to main content
Download PDF

Extracellular vesicles in venous thromboembolism and pulmonary hypertension

Journal of Nanobiotechnology volume 21, Article number: 461 (2023) Cite this article

Abstract

Venous thromboembolism (VTE) is a multifactorial disease, and pulmonary hypertension (PH) is a serious condition characterized by pulmonary vascular remodeling leading with increased pulmonary vascular resistance, ultimately leading to right heart failure and death. Although VTE and PH have distinct primary etiologies, they share some pathophysiologic similarities such as dysfunctional vasculature and thrombosis. In both conditions there is solid evidence that EVs derived from a variety of cell types including platelets, monocytes, endothelial cells and smooth muscle cells contribute to vascular endothelial dysfunction, inflammation, thrombosis, cellular activation and communications. However, the roles and importance of EVs substantially differ between studies depending on experimental conditions and parent cell origins of EVs that modify the nature of their cargo. Numerous studies have confirmed that EVs contribute to the pathophysiology of VTE and PH and increased levels of various EVs in relation with the severity of VTE and PH, confirming its potential pathophysiological role and its utility as a biomarker of disease severity and as potential therapeutic targets.

Graphical Abstract

Introduction

Extracellular vesicles (EVs) are membrane-bound structures originating from various cell types. They stem from cell membranes and cytoplasmic material and are released into the extracellular space [1]. EVs are classified into different subgroups according to their size and biogenesis [2,3,4]. Microvesicles (MVs) or microparticles (MPs), 0.1–1 μm in diameter, are thought to bud off directly from the plasma membrane (PM) [4]. Exosomes, less than 150 nm in diameter, are produced in multivesicular endosomes or bodies (MVBs), which can then fuse with the PM and be secreted into extracellular surroundings [2]. EVs are composed of the biological contents and surface molecules from their parent cells including nucleic acids, proteins and lipids, thereby affecting a variety of intercellular communication pathways [5, 6].

Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as VTE is a multifactorial disease [7, 8], affecting 10 million individuals each year and representing the third leading vascular disease after acute myocardial infarction and stroke [9, 10]. Virchow’s triad proposed that VTE is caused by blood hypercoagulability, vascular wall damage and impaired blood flow [11].

Pulmonary hypertension (PH) is a serious condition characterized by pulmonary vascular remodeling leading to increased pulmonary vascular resistance, ultimately resulting in right ventricle pressure overload and failure substantially reducing the duration and the quality of life [12]. Although there are many sub-types of pulmonary hypertension beyond the scope of this review, the pathophysiology is recognized as complex, involving multiple pathways and triggers with sometimes genetic predisposition as well as with a central role of endothelial dysfunction (ED) as a contributing factor [13].

VTE and PH are two distinct diseases, but they are both associated with an abnormal function of the vasculature, and chronic thromboembolic pulmonary hypertension (CTEPH) as group 4 PH is a long-term complication of unresolved PE[14]. A similarity between VTE and PH is that both conditions are associated with thrombosis in the blood circulatory system. VTE refers to primary thrombus formation in deep veins [7], while PH is caused by abnormally elevated pulmonary artery pressure due to vascular constriction and remodeling causing obliteration of the distal pulmonary vasculature with secondary associated thrombi formation [15]. In both VTE and PH, the formation of thrombosis can lead to disorders of the blood circulation system, which causes a series of severe symptoms and complications.

The distinction between the two diseases mainly includes the following aspects. First, they occur at different sites. VTE occurs mainly in the deep veins of the lower limbs and usually causes symptoms like lower limb swelling, pain and varicose veins [7]. PH, which occurs in the pulmonary blood vessels, causes symptoms such as dyspnea, chest pain and syncope [13]. Secondly, the etiology of VTE and PH also vary from each other. The main causes of VTE include prolonged immobilization, surgery, tumor and genetic factors [11]. However, the etiology of PH has greater complexity and may be related to various factors such as genetics, thromboembolism and the interactions between environmental factor(s) and human body, [13]. While the treatment of VTE consists essentially of anticoagulation, the treatment of PH requires an individualized approach including drugs that interfere with the lung vascular remodeling process. In addition, there are also differences in the prognosis of VTE and PH. Although both diseases can cause severe complications, the prognosis of PH is generally worse than VTE. PH is a chronic disease with a relatively slow progression and is more difficult to treat [15]. In contrast, VTE can often be controlled by timely anticoagulation therapy and active rehabilitation measures [7].

EVs play a key regulatory role in the occurrence and progression of VTE and PH. Thrombosis is one of the main characteristics of VTE, and EVs can carry coagulation factors and platelet-activating factors, which can promote the formation of thrombosis. EVs can activate endothelial cells and platelets, increase the adhesiveness of vascular endothelial cells and platelet aggregation, and further promote thrombus formation. Moreover, EVs can also activate inflammatory responses and immune responses, leading to inflammation and damage in the vascular wall, further promoting the development of VTE. In patients with PH, it was found that the content of EVs in the blood and lung tissue was significantly increased. These EVs may arise from multiple cell types, including pulmonary artery endothelial cells, smooth muscle cells, and inflammatory cells. EVs can influence the pathogenesis of PH through several mechanisms by carrying bioactive molecules such as inflammatory factors, miRNA and cytokines. Moreover, EVs can also affect vascular remodeling and pulmonary artery constriction by regulating the function of vascular endothelial cells.

In this review, we summarize the current knowledge concerning the role of EVs in two pathophysiologic conditions that can sometimes be linked and co-exist in the same subjects: VTE and PH. We aim to determine the similarities and distinctions between these two diseases and to discuss the pathophysiologic roles of EVs as well as their potential as biomarkers for VTE and PH. For simplicity, this review will refer to both MVs and exosomes presented in published studies as EVs.

Mechanistic contribution of EVs in the pathophysiology of VTE

Thus far, many studies have confirmed that circulating EVs are increased in VTE patients, suggesting that EVs might be involved in the pathophysiology of VTE [16,17,18,19,20].

EVs and hypercoagulability or thrombosis

There is a close correlation between EVs and hypercoagulability or thrombosis. EVs are involved in the regulation of hypercoagulability and thrombosis by carrying and releasing blood coagulation-related molecules, and by interacting with target cells such as platelets, leukocytes and endothelial cells.

All circulating EVs display inherent procoagulant properties as they provide an anchoring surface membrane for the assembly of components from the coagulation cascade [21]. Furthermore, the potential for promoting coagulation is increased by the exposure of negatively charged membrane glycerophospholipids, particularly phosphatidylserine (PS), and the expression of key tissue factor (TF) involved in the coagulation cascade [22, 23]. Transmembrane glycoprotein TF, as a receptor for FVII/VIIα, is the primary initiator of coagulation in vivo. Subsequently, the TF/FVIIα complex activate both FX and FIX to facilitate thrombin formation [24]. Circulating EVs bearing TF mainly originated from monocytes and tumor cells [25,26,27] thus contributing to the greater incidence of VTE associated with cancer. Although circulating TF-positive EVs are normally relatively low in number in physiological conditions, their number rises in pathological conditions, particularly cancer and infectious diseases. In addition, the density of TF on EVs has been shown to be higher than at the surface of their parental cells [27]. Furthermore, PS that resides in the inner leaflet of membrane bilayer can increase the ability of TF to initiate coagulation [20]. In contrast, cells activation or apoptosis lead to the translocation of PS to the outer leaflet of the membrane bilayer and increase membrane blebbing, the forming of irregular bulge(s) in the cell membrane by localized decoupling of the cytoskeleton from the cell membrane, and subsequent EVs shedding. Indeed, the exposure of PS at the membrane surface facilitates the electrostatic interaction with the electropositive γ-carboxyglutamic acid (GLA) domains in the clotting proteins (FVII, X, IX and II) [28]. In addition, PS accelerates the formation of the tenase and prothrombinase complexes, ultimately promoting thrombin formation [19].

Of note, circulating EVs mainly originate from platelets, red blood cells, leukocytes, and endothelial cells. EVs of different origins and released in different pathophysiological conditions may have different procoagulant activities.

Platelet-derived EVs

As the most abundant EVs in human body, platelet-derived EVs (PEVs) account for 70–90% of circulating EVs in the blood [29, 30]. PEVs express PS, TF and receptors for coagulation factors at their surface membranes, thus inducing procoagulant properties [31]. PEVs membranes exhibit a procoagulant activity 50- to 100-fold higher than in activated platelets [32]. P-selectin, CD40 and CD40 ligands (CD40L or CD154) at the surface of activated platelets can interact with their respective receptors presented in leukocytes (P-selectin glycoprotein ligand-1 (PSGL-1) or CD40). This interaction induce the upregulation of leukocytes-derived TF, thereby promoting the thrombotic progression [33]. Therefore, Lin et al. proposed that these adhesive molecules presented at the surface of PEVs are also important for monocyte aggregation [31]. They further indicated that PEVs can trigger cell-mediated thrombogenicity and lead to the generation of pro-coagulant TF-bearing EVs secreted by monocytes [31].

In addition to facilitating thrombin formation by presenting a procoagulant surface factors, PEVs and red blood cell-derived EVs (RBC-EVs) can initiate the formation of thrombin in a FXII-dependent manner in vitro [34] and in FXI-dependent manner in human endotoxemia [35]. In an experimental model of venous thrombosis in mice, Ramacciotti et al. found a positive correlation between PEVs infusion and thrombus weight, while in contrast the infusion of leukocyte-derived EVs (LEVs) negatively correlated with thrombus weight [36]. Therefore, they hypothesized that PEVs may be a marker for thrombosis in this experimental model, while LEVs were involved in thrombus resolution.

Thrombin can activate platelets and also promote the release of PEVs. As it was shown that thrombin-stimulated platelets produced 2.71 times more PEVs than unstimulated platelets in vitro [37]. FBXW7 (F-Box and WD repeat domain containing 7) and EFNA1 (Ephrin A1) were reported to be able to regulate endothelial barrier function and endothelial proliferation [38, 39]. After being activated by thrombin, platelets can release a large amounts of the miR-223 in PEVs, and PEVs then deliver functional Ago2 miR-223 complexes to human umbilical vein endothelial cells (HUVECs) in turn reducing the endothelial expression of its mRNA targets FBXW7 and EFNA1, at the transcriptional and protein level, this can further promote endothelial dysfunction. Furthermore, miR-223 in PEVs secreted by platelets can facilitate endothelial cells apoptosis by downregulating the expression of vascular insulin-like growth factor 1 receptor (IGF-1R) and promote thrombin formation [40].

Red blood cell-derived EVs

Erythrocytes spontaneously produce PS-positive EVs during their maturation. Under storage conditions for transfusion, erythrocytes release more EVs [41]. However, in a proteomic analysis of RBC-EVs, TFs were not identified and their ability to increase thrombosis generation has been shown even at alow expression level or absence of TF [42, 43]. Moreover, it has been mentioned earlier that RBC-EVs can promote thrombin generation in a FVII-dependent manner [34]. Furthermore, RBC-EVs accelerate the generation of thrombin through the interaction with FXI in human endotoxemia [35], sickle cell disease [43] and donor blood units samples [44]. Von Willebrand factor (vWF) is a macromolecular protein produced by platelets and endothelial cells. vWF plays an important role in the process of blood clotting by facilitating platelet aggregation and the initiation of the clotting process [45]. Straat et al. proposed that RBC-EVs are the main source of von Willebrand factor (vWF), which takes a part in both cell adhesion and thrombin formation [46].

Monocyte-derived EVs

Monocyte-derived EVs (MEVs) exhibit both PS and TF at their membrane surface and the prothrombinase activity of TF-positive MEVs was 2.8-fold higher than for TF-negative PEVs [47]. As for PEVs, MEVs were confirmed to modulate blood clot formation in vitro [48, 49], although it might be different from thrombus formation in vivo. In pathological conditions, increased circulating MEVs play a more significant role in thrombin formation [50].

MEVs can increase fibrin network density and increase clot resistance to fibrinolysis [47]. Additionally, MEVs could also express adhesive molecules such as CD15 or PSGL-1, thereby enabling the docking to activated platelets by binding to P-selectin and leading to TF accumulation in developing thrombus and fibrin formation [51]. Finally, TF-positive MEVs can also interact with neutrophils and stimulate their procoagulant activity [52].

Endothelial cell-derived EVs

Endothelial-derived EVs (EEVs) bearing both TF and PS are released when endothelial cells (ECs) were activated. EEVs play a vital role in thrombogenesis by binding to monocytes [53, 54]. EEVs interact with monocytes through the interplay of ICAM-1 on EEVs and β2 integrins on monocytes, stimulating TF expression by monocytes [55]. Additionally, EEVs depend on the expression of super-large vWF to promote and stabilize platelet aggregates [56]. Oxidized phospholipids in EEVs exposed to oxidative stress might be particularly active in mediating both monocyte adherence to ECs and the activation of neutrophils, which are involved in thrombus formation [57, 58].

EVs in endothelial dysfunction

The vascular wall damage component from the initial Virchow’s triad is now more broadly recognized as endothelial dysfunction (ED). We now know that the vascular ECs critically contribute to the maintenance of cardiovascular homeostasis by releasing vasoconstrictors and vasodilators and by regulating inflammation and thrombosis. ED is an initiating event in the occurrence and development of cardiovascular diseases [59]. In addition, it is regarded as an indispensable contributor in the development of VTE. ED is characterized by disruption of NO production, inflammation and coagulation, which ultimately influences angiogenesis and apoptosis. During ED, numerous functions of ECs are disturbed and increasing evidence in the literatures have established the potential role of circulating EVs in the development of ED [59,60,61].

Platelet-derived EVs

PEVs together with abnormal shear stress can stimulate ECs in turn secreting cytokines and enhancing ICAM-1, VCAM-1and E-selectin expression [62]. PEVs containing arachidonic acid can activate adjacent platelets and ECs [63]. CCL5 (RANTES) is a cytokine that regulates cell activity by binding to specific cell surface receptors. PEVs can deliver CCL5 (RANTES) to the inflamed and atherosclerotic endothelium, triggering monocytes adhesion [64].

Importantly, most of the miRNAs in human plasma was localized in EVs [65]. Diehl et al. demonstrated that the predominant amount of plasma miRNA was associated with EVs and only small amounts were detected in EVs-free plasma underlining the importance of EVs as miRNA transport vesicles in circulation [65]. They found that plasma preparations contained 5200 EVs/uL, 41 to 45% of circulating EVs were from platelet, 28% from leucocyte, and 8% from endothelial origin. PEVs are seen as important vesicles to transfer platelet-specific miRNAs to ECs. Diehl et al. found that activated platelets can release functional miRNAs to promote ICAM-1 expression in ECs [66]. Bao et al. found that miR-142-3p and miR-223-3p were increased in PEVs in hypertension [37]. In vitro studies showed that PEVs containing BCLAF1-targeting miR-142-3p promoted ECs proliferation via BCL2 and Bax. In addition to promoting thrombin formation, miR-233 can induce vascular ECs apoptosis by targeting IGF-1R [40]. Another in vitro study however found that PEVs could reduce ECs activation. Lee et al. found that PEVs transferred into ECs can inhibit the expression of ICAM-1 in TNF-α-stimulated HUVECs by regulating the MAPK and NF-κB signaling pathways through miR-223 [67].

Red blood cell-derived EVs

RBC-EVs are structurally and functionally distinct from their parenting RBCs [68]. RBC-EVs contain a significant amount of hemoglobin (Hb), which confers to RBC-EVs physiological properties that are closer to cell-free Hb than intact RBC, especially in terms of interactions with nitric oxide (NO) [41]. NO was considered as the endothelial-derived relaxing factor, modulating vascular tone and reducing platelet activation and cellular vascular adhesion [69]. Gladwin et al. found that RBC-EVs can scavenge NO many times faster than RBC [70] in relation with higher Hb concentration in smaller RBC-EVs [71]. Moreover, RBC-EVs are more accessible to close to ECs, subsequently scavenge NO [41].

Straat et al. found that monocytes binding or phagocytosing RBC-EVs upregulate ICAM-1 and E-selection expression in ECs, and this process is mediated by β-integrin [46]. However, RBC-EVs alone or co-incubated with neutrophils cannot activate ECs, suggesting that the effect was specific for monocytes.

Monocyte-derived EVs

Various monocytes stimulation can alter EVs cargo but not their size or concentration [72]. LPS-stimulated MEVs can promote the expression of ICAM-1, CCL2, and IL-6 through an NF-κB mechanism involving TLR4. In another study, the same stimulus promoted ICAM-1, VCAM-1, and E-selectin expressions by the ERK1/2 and NF-κB pathways [73]. MEVs are capable of autocrine activation, inducing the production of superoxide anions, the release of cytokines and the activation of NF-κB, ultimately leading to EC dysfunction [74]. Apoptotic MEVs enhance the release of NO from ECs. This process involves the activation of PI3-kinase and ERK1/2 promoting the expression of caveolin-1 albeit not its phosphorylation. Interestingly, MEVs treatment leads to an increase in protein nitration at the tyrosine residue participating in ED [75].

Endothelial cell-derived EVs

TNF-α-stimulated EEVs interact with ECs to induce the expression of IL-10 [72], ICAM-1 as well as pro-apoptotic molecules [76] leading to monocytes adhesion. EEVs produced under pathologic hyperglycemic conditions show increased NADPH oxidase activity and contain higher levels of ROS. TNF-α-stimulated EEVs stimulate endothelial inflammation through a NADPH oxidase-ROS-p38 signaling pathway and upregulate ICAM-1 and VCAM-1 expression as well as promote monocyte adhesion [77]. Activated EEVs by high glucose and AngII aggravated ED by increasing ERK1/2 signaling and reducing eNOS protein expression level in mice aortas [78]. Zernecke et al. found that miR-126 enriched in apoptotic bodies can interact with adjacent ECs and decrease atherosclerosis in mice [79]. However, Jansen et al. found that EEVs containing miR-222 reduced ED through the downregulation of ICAM-1 [80]. The apparent conflictual role of EEVs may partly relate to the specific pathophysiologic conditions and the known specialization of EVs, ECs of different origins within different conditions produce EVs with different contents and functions [81].

EVs and impaired blood flow

PS-positive EVs with or without TF are mostly cleared by the spleen [82,83,84]. Reduced blood flow promotes EVs accumulation at the endothelial surface and reduce the clearance of circulating EVs. Furthermore, venous blood stasis leads to hypoxia in the valvular pockets of large veins where venous thrombi are generated. Hypoxia can in turn lead to ED with increased EVs production contributing thrombin formation [11].

Mechanistic role(s) of EVs in the pathophysiology of PH

Numerous studies found that PH patients exhibit higher levels of circulating EVs than healthy subjects [85,86,87,88,89,90,91]. Further studies found that EVs play a crucial role in the pathogenesis of PH [92].

Healthy mice injected with EVs harvested from the plasma or lung tissues of mice with monocrotaline-induced PH (MCT-PH) subsequently developed PH [93, 94]. Blair et al. have found that circulating EVs from late stage PH rats stimulated ICAM-1 expression in the pulmonary arterial endothelium but not in the pulmonary microvascular endothelium [95]. These results were consistent with previous report supporting molecular and functional heterogeneity in pulmonary ECs [96]. However, whether EVs can induce the expression of other inflammatory molecules in the microvascular endothelium or not needs further studies. In addition, the EVs isolated from MCT-PH mice were mainly derived from pulmonary ECs [93]. There were no differences in the number of lung tissue-derived EVs and blood plasma-derived EVs isolated from MCT-injured or vehicle-treated mice, but qualitative differences were observed [93].

Indeed, lung-derived EVs from MCT-induced PH, but not plasma-derived EVs, showed higher and different endothelial mRNA expression such as PDGF, BNPR2 and eNOS. Furthermore, miRNA microarray analysis was performed on EVs-based miRNAs, and found that EVs from both MCT-PH rats and PH patients contained elevated miRNAs, which may contribute to the development of PH [97]. The types of miRNAs commonly increased in EVs derived from MCT-PH rats and IPAH patients were found to include miR-17–92 cluster, miR-21, and miR-145. Previous studies have suggested their roles in pulmonary vascular remodeling although the underlying mechanisms linking these miRNA and the development of PH remains poorly known and require further studies to evaluate their potential for treatment of PH. Interestingly, the resource of EVs was mainly from platelets and erythrocytes in hypoxia-induced PH mice [98]. Circulating EVs generally refer to the extracellular vesicles that are found in the bloodstream or other bodily fluids. Circulating EVs derived from platelets and red blood cells in blood of hypoxia-induced PH mice can induce ED by both decreasing NO production and increasing oxidative stress in pulmonary EC [98].

As for VTE, hypercoagulability and ED may partly contribute to the pathogenesis of PH [92]. In the following section of this review, we will summarize the role of EVs on pulmonary arterial smooth muscle cells (PASMCs) and the role of EVs as a mean of crosstalk between pulmonary arterial endothelial cells (PAECs) and PASMCs in the development of PH.

Endothelial cells-derived EVs

Previous research has confirmed that ED could lead to an increased PAECs-derived EVs secretion, which transferred to PASMCs to induce its over-proliferation and conversion to an apoptosis-resistant phenotype [99]. In addition, PAECs-derived EVs miR-210-3p contribute to the proliferation of PASMC and the development of PH induced by hypoxia [100]. Su et al. have demonstrated that miR-1249 from PAECs-derived EVs mediated cigarette smoke-induced PH through the inhibition of the HDAC10-NFκB-CaSR cascade [101]. Besides miRNA, spermine enrichment at the outer surface and cytosol of PAECs-derived EVs mediated smoking-induced PH partially through CaSR [102]. However, EVs may also exert a protective role in PH. EVs can either promote or prevent PH based on their content. Endothelial cells-derived EVs reduce the proliferation and migration of vascular smooth muscle cells (VSMCs), and subsequent neointima formation by delivering functional miR126 into recipient VSMCs. In addition, endothelial cells-derived EVs transferred miR195 to SMCs, and miR-195 inhibit the proliferation of SMCs through 5-HTT [103]. Krüppel-like factor 2 (KLF2) is a transcription factor and plays a critical role in the regulation of lung function and development when it is activated by shear stress [104]. Sindi et al. found that KLF2-induced PAECs-derived EVs attenuate pulmonary vascular remodeling through the combined action of miR-181a-5p and miR-324-5p [104]. ECs overexpressing KLF2 induced the production of miRNA143/145 that are then delivered to VSMCs via EVs and depress the target genes expression to reduce atherosclerosis, and these target genes come from the research reports and target prediction including ELK1 (ETS transcription factor ELK1), KLF4 (Kruppel-like factor 4), CAMK2d (calcium/calmodulin-dependent protein kinase type II subunit delta), CFL1 (cofilin 1), PHACTR4 (phosphatase and actin regulator 4), SSH2 (slingshot protein phosphatase 2) and MMP3 (matrix metallopeptidase 3) [105].

Smooth muscle cells-derived EVs

Zheng et al. have found that smooth muscle cells (SMCs) exposed to oxLDL enhance their expression of KLF5 that in turn reduced miR143/145 and miR211/222 expression while increasing miR155 and miR146a expression. EVs-mediating miR155 transfer from SMCs to ECs changed the endothelial barrier by inhibiting the expression of the tight junction protein, especially ZO-1, consequently increasing microvascular permeability and promoting atherosclerosis [106]. PASMC-derived EVs were internalized by PAECs and the mRNA cargo transfer can promote the endothelial-to-mesenchymal transition in HPAECs contributing to the development of PH [107]. MiR-221/222 as content of Human aortic smooth muscle cells-derived exosomes inhibited the autophagy of HUVECs by inhibiting the expression of PTEN and subsequently activating Akt signaling [108]. EVs containing miR143 derived from PASMCs may be transferred to PAECs to facilitate ECs migration and angiogenesis [109].

Other cells-derived EVs

Other sources of EVs are involved in the vascular remodeling as well. PEVs firmly bound to resting SMCs to facilitate the adhesion of monocyte to SMCs and induce the secretion of IL-6 leading to a pro-inflammatory SMCs phenotype and stimulating vascular remodeling [110]. As a scavenger receptor, the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) can promote endothelial dysfunction and contribute to the development of atherosclerotic cardiovascular disease [111]. A recent research has found that plasma-derived EVs can drive hypoxic PH by transferring LOX-1 cargo to trigger phenotypic switching of PASMCs from contractile phenotype to proliferative phenotype [112]. MEVs may transfer caspase-1 into the cytosol of ECs and SMCs in turn inducing apoptosis [113]. Sharma et al. have demonstrated that EVs derived from HIV-infected monocyte-derived macrophages exposed to drugs of abuse can induce the proliferation of human PASMCs [114].

The differences in the role of EVs in VTE and PH

As mentioned above, EVs play important roles in VTE and PH. However, due to the differences between VTE and PH pathogenesis, there are different roles played by EVs in these two diseases. The differences may be related to the underlying mechanism and clinical manifestations of both diseases, and further investigation of the mechanism of action and regulatory pathway of EVs are important for an in-depth understanding of the occurrence and development of VTE and PH.

In VTE, the critical role of EVs is thought to promote thrombosis and ED [16]. It has been shown that EVs can release platelet-activating factors and coagulation factors during thrombus formation, thus promoting the occurrence of platelet aggregation and coagulation cascade [33, 46, 50, 56]. Moreover, EVs can also activate ECs, leading to the development of vascular ED and the occurrence of inflammatory responses, further promoting thrombosis [62, 63, 74].

In contrast, in PH, the role of EVs is much more complex and diverse. Studies have shown that increased EVs release exists in the circulatory system of patients with PH [81]. These EVs can carry a variety of bioactive molecules, such as cytokines, growth factors and miRNA, and participate in the development and development of PH by interacting with target cells [100, 102, 104, 112]. First, EVs can promote pulmonary vascular contraction and pulmonary vascular remodeling by activating the SMCs and ECs of the pulmonary arteries, thus leading to the development of PH [107]. Second, EVs can also participate in the pathological process of PH by regulating the immune response and inflammatory response.

EVs as biomarkers for VTE and PH

A large number of previous studies have measured and compared the levels of EVs originating from different cell types in patients versus healthy subjects and recommended EVs as a biomarker in VTE and PH. The recognition of EVs as biomarkers for VTE have been elegantly reviewed in 2012 by Rautou et al. [19]. Hence, Tables 1 and 2 recapitulate the major findings highlighting the place of EVs as biomarkers for VTE from 2012 up-to-date for VTE and since 2008 for PH.

EVs (endothelium, platelet, monocyte, etc.) and TF-EVs as a biomarker for VTE

See Table 1

Table 1 Studies measuring EVs in patients with venous thromboembolism
Full size table

EVs (endothelium, platelet, etc.) as a biomarker for PH

See Table 2

Table 2 Studies measuring EVs in pulmonary hypertensionpatients
Full size table

EVs as therapeutic application for VTE and PH

Extracellular vesicles can be propagated to different tissues and organs via blood circulation and interact with target cells. Thus, the use of extracellular vesicles for disease therapy or as carriers to deliver therapeutic agents has great potential.

There are evidences that bone marrow-derived endothelial progenitor cells (EPCs) can contribute substantially to the resolution of thrombosis [132]. Previous studies have demonstrated that miR-126 can improve endothelial progenitor cells migration and angiogenesis, and promote the recruitment of endothelial progenitor cells in venous thrombosis [133]. Sun et al. found that translocation of miR-126 into EPCs-derived EVs by electroporation can promote dissolution and recanalization of DVT [134]. Furthermore, PEVs carrying miR-320 can relieve inflammation and thrombosis by promoting the mobility of ECs [66]. PEVs carrying miR-223 can also inhibit ICAM-1 expression in ECs during inflammation [67].

Numerous studies have shown that mesenchymal stem cell (MSC)-derived EVs can be used as a therapeutic strategy for the improvement of PH. Chen et al. demonstrated that intravenous injection of MSC-derived EVs significantly improved MCT-induced rat PAH[135]. Aliotta et al. also confirmed that MSC-derived EVs could reverse progression of MCT-induced mice PAH [136]. It has been shown that treatment with MSC-derived EVs can significantly inhibit vascular remodeling in PAH patients by reducing PASMCs proliferation and right ventricular systolic as well as pulmonary arterial systolic pressure [137]. MSC-derived EVs have also been proved to reverse the development of PH in mice treated with EPCs from PAH mice [138]. In addition to MSCs, it has been reported that endothelial cells-derived EVs transferred miR195 to SMCs can prevent the proliferation and migration of SMCs and contribute to the improvement of PH [103].

Future challenges

EVs play critical roles in VTE and PH, mainly involved in the pathogenesis of both diseases, and are potentially suitable to be diagnostic markers and therapeutic targets. However, EVs from different sources vary widely in composition and cargo. Most of the studies included in this review mainly investigated the role of miRNAs as the cargo of EVs in the pathogenesis of VTE and PH. However, studies on other important EVs content such as protein, lipids and DNA are lacking and require further research and exploration. The field of EVs research expands very rapidly, but due to the inherent characteristics of EVs, there are remaining challenges with their use in the clinical detection of disease activity as well as therapy. The current methods used to isolate and analyze EVs lack consistency and a standardized approach with quality controls of EVs preparation is required. The content of EVs varies considerably from the parent cells and EVs selection should be designed according to the desired target molecules of the recipient cells. Moreover, differences in the complexity and severity of the disease may have some impact on EVs as biomarkers and therapeutic approaches. Despite these limitations, further identification of EVs and corresponding cargo can help to discover clinically useful biomarkers and develop new treatments for disease.

Conclusion

We have reviewed the known potential roles of EVs in two pathophysiologically linked conditions, VTE and PH. In both conditions there is solid evidence that EVs contribute to vascular endothelial dysfunction, inflammation, thrombosis and cellular activation and communications. The roles and importance of EVs substantially differ between studies depending on experimental conditions and parent cell origins of EVs that modify the nature of their cargo. Animal models have clearly established that EVs contribute to the pathophysiology of VTE and PH. Human studies have found increased levels of various EVs in relation with the severity of VTE and PH, confirming its potential pathophysiological role and its utility as a biomarker of disease activity and severity. However, we failed to identify clear disparities between EVs in VTE versus PH such that a distinctive signature is currently not evident. Further research should help to delineate the distinctions between EVs in VTE versus PH to develop more specific markers of disease and exploring potential novel therapeutic targets.

Availability of data and materials

Not applicable.

Abbreviations

EVs:

Extracellular vesicles

MVs:

Microvesicles

MPs:

Microparticles

PM:

Plasma membrane

MVBs:

Multivesicular endosomes or bodies

VTE:

Venous thromboembolism

PH:

Pulmonary hypertension

DVT:

Deep vein thrombosis

PE:

Pulmonary embolism

PS:

Phosphatidylserine

TF:

Key tissue factor

PEVs:

Platelet-derived EVs

PSGL-1:

P-selectin glycoprotein ligand-1

RBC-EVs:

Red blood cell-derived EVs

LEVs:

Leukocyte-derived EVs

HUVECs:

Human umbilical vein endothelial cells

vWF:

Von Willebrand factor

MEVs:

Monocyte-derived EVs

EEVs:

Endothelial EVs

ED:

Endothelial dysfunction

Hb:

Hemoglobin

MCT-PH:

Monocrotaline-induced PH

PASMCs:

Pulmonary arterial smooth muscle cells

PAECs:

Pulmonary arterial endothelial cells

EPCs:

Endothelial progenitor cells

References

  1. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Li G, Chen T, Dahlman J, Eniola-Adefeso L, Ghiran IC, Kurre P, et al. Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases. J Extracell Vesicles. 2023;12(2):e12305.

    Article  PubMed  Google Scholar 

  4. Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23(4):236–50.

    Article  CAS  PubMed  Google Scholar 

  5. Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  7. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20(4):248–62.

    Article  PubMed  Google Scholar 

  8. Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.

    Article  PubMed  Google Scholar 

  9. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580–90.

    Article  Google Scholar 

  10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–73.

    Article  CAS  PubMed  Google Scholar 

  11. Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hamostaseologie. 2017;37(1):25–35.

    Article  PubMed  Google Scholar 

  12. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Poch D, Mandel J. Pulmonary hypertension. Ann Intern Med. 2021;174(4):ITC49–64.

    Article  PubMed  Google Scholar 

  14. Lutsey PL, Evensen LH, Thenappan T, Prins KW, Walker RF, Farley JF, et al. Incidence and risk factors of pulmonary hypertension after venous thromboembolism: an analysis of a large health care database. J Am Heart Assoc. 2022;11(14):e024358.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.

    Article  PubMed  Google Scholar 

  16. Ye SL, Li WD, Li WX, Xiao L, Ran F, Chen MM, et al. The regulatory role of exosomes in venous thromboembolism. Front Cell Dev Biol. 2022;10:956880.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost. 2013;11(Suppl 1):24–35.

    Article  PubMed  Google Scholar 

  18. Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A. 2016;89(2):111–22.

    Article  CAS  PubMed  Google Scholar 

  19. Rautou PE, Mackman N. Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol. 2013;6(1):91–101.

    Article  CAS  PubMed  Google Scholar 

  20. Zhou L, Qi XL, Xu MX, Mao Y, Liu ML, Song HM. Microparticles: new light shed on the understanding of venous thromboembolism. Acta Pharmacol Sin. 2014;35(9):1103–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Reddy EC, Rand ML. Procoagulant phosphatidylserine-exposing platelets in vitro and in vivo. Front Cardiovasc Med. 2020;7:15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96(5):2311–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost. 2010;36(8):865–75.

    Article  CAS  PubMed  Google Scholar 

  25. Shustova ON, Antonova OA, Golubeva NV, Khaspekova SG, Yakushkin VV, Aksuk SA, et al. Differential procoagulant activity of microparticles derived from monocytes, granulocytes, platelets and endothelial cells: impact of active tissue factor. Blood Coagul Fibrinolysis. 2017;28(5):373–82.

    Article  CAS  PubMed  Google Scholar 

  26. Khaspekova SG, Antonova OA, Shustova ON, Yakushkin VV, Golubeva NV, Titaeva EV, et al. Activity of tissue factor in microparticles produced in vitro by endothelial cells, monocytes, granulocytes, and platelets. Biochemistry (Mosc). 2016;81(2):114–21.

    Article  CAS  PubMed  Google Scholar 

  27. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206(9):1913–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):15–26.

    Article  CAS  PubMed  Google Scholar 

  29. Boilard E, Duchez AC, Brisson A. The diversity of platelet microparticles. Curr Opin Hematol. 2015;22(5):437–44.

    Article  CAS  PubMed  Google Scholar 

  30. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007;137(1):36–48.

    Article  CAS  PubMed  Google Scholar 

  31. Lin HC, Chang HW, Hsiao SH, Chou ML, Seghatchian J, Burnouf T. Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. Transfus Apher Sci. 2015;53(2):246–52.

    Article  PubMed  Google Scholar 

  32. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97(3):425–34.

    Article  CAS  PubMed  Google Scholar 

  33. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129(3):263–6.

    Article  CAS  PubMed  Google Scholar 

  34. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renné T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10(7):1355–62.

    Article  PubMed  Google Scholar 

  35. Mooberry MJ, Bradford R, Hobl EL, Lin FC, Jilma B, Key NS. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. J Thromb Haemost. 2016;14(5):1031–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr, et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost. 2009;101(4):748–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bao H, Chen YX, Huang K, Zhuang F, Bao M, Han Y, et al. Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p. FASEB J. 2018;32(7):3912–23.

    Article  CAS  PubMed  Google Scholar 

  38. Pronk MCA, Majolée J, Loregger A, van Bezu JSM, Zelcer N, Hordijk PL, et al. FBXW7 regulates endothelial barrier function by suppression of the cholesterol synthesis pathway and prenylation of RhoB. Mol Biol Cell. 2019;30(5):607–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wiedemann E, Jellinghaus S, Ende G, Augstein A, Sczech R, Wielockx B, et al. Regulation of endothelial migration and proliferation by ephrin-A1. Cell Signal. 2017;29:84–95.

    Article  CAS  PubMed  Google Scholar 

  40. Wang H, Wang Q, Kleiman K, Guo C, Eitzman DT. Hematopoietic deficiency of miR-223 attenuates thrombosis in response to photochemical injury in mice. Sci Rep. 2017;7(1):1606.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Said AS, Doctor A. Influence of red blood cell-derived microparticles upon vasoregulation. Blood Transfus. 2017;15(6):522–34.

    PubMed  PubMed Central  Google Scholar 

  42. Bosman GJ, Lasonder E, Luten M, Roerdinkholder-Stoelwinder B, Novotný VM, Bos H, et al. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion. 2008;48(5):827–35.

    Article  CAS  PubMed  Google Scholar 

  43. van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Rubin O, Delobel J, Prudent M, Lion N, Kohl K, Tucker EI, et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion. 2013;53(8):1744–54.

    Article  CAS  PubMed  Google Scholar 

  45. Rayner SG, Scholl Z, Mandrycky CJ, Chen J, LaValley KN, Leary PJ, et al. Endothelial-derived von Willebrand factor accelerates fibrin clotting within engineered microvessels. J Thromb Haemost. 2022;20(7):1627–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Straat M, van Hezel ME, Böing A, Tuip-De Boer A, Weber N, Nieuwland R, et al. Monocyte-mediated activation of endothelial cells occurs only after binding to extracellular vesicles from red blood cell products, a process mediated by β-integrin. Transfusion. 2016;56(12):3012–20.

    Article  CAS  PubMed  Google Scholar 

  47. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9(11):2251–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Meisel SR, Xu XP, Edgington TS, Cercek B, Ong J, Kaul S, et al. Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. J Atheroscler Thromb. 2011;18(7):596–603.

    Article  CAS  PubMed  Google Scholar 

  49. Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122(2):558–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Stojkovic S, Thulin Å, Hell L, Thaler B, Rauscher S, Baumgartner J, et al. IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. Thromb Haemost. 2017;117(7):1379–90.

    Article  PubMed  Google Scholar 

  51. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Egorina EM, Sovershaev MA, Olsen JO, Østerud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood. 2008;111(3):1208–16.

    Article  CAS  PubMed  Google Scholar 

  53. Musolino C, Alonci A, Allegra A, Spatari G, Bellomo G, Tringali O, et al. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications. Am J Hematol. 1998;57(2):109–12.

    Article  CAS  PubMed  Google Scholar 

  54. Smith A, Quarmby JW, Collins M, Lockhart SM, Burnand KG. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost. 1999;82(6):1593–9.

    CAS  PubMed  Google Scholar 

  55. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 2002;99(11):3962–70.

    Article  CAS  PubMed  Google Scholar 

  56. Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005;3(6):1301–8.

    Article  CAS  PubMed  Google Scholar 

  57. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002;22(1):101–7.

    Article  CAS  PubMed  Google Scholar 

  58. Patel KD, Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992;267(21):15168–75.

    Article  CAS  PubMed  Google Scholar 

  59. Lovren F, Verma S. Evolving role of microparticles in the pathophysiology of endothelial dysfunction. Clin Chem. 2013;59(8):1166–74.

    Article  CAS  PubMed  Google Scholar 

  60. Liu ML, Williams KJ. Microvesicles: potential markers and mediators of endothelial dysfunction. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):121–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. van der Vorst EPC, de Jong RJ, Donners MMPC. Message in a microbottle: modulation of vascular inflammation and atherosclerosis by extracellular vesicles. Front Cardiovasc Med. 2018;5:2.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158(2):277–87.

    Article  CAS  PubMed  Google Scholar 

  63. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99(9):2118–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25(7):1512–8.

    Article  CAS  PubMed  Google Scholar 

  65. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93(4):633–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Gidlöf O, van der Brug M, Ohman J, Gilje P, Olde B, Wahlestedt C, et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood. 2013;121(19):3908-17 S1-26.

    Article  PubMed  Google Scholar 

  67. Li J, Tan M, Xiang Q, Zhou Z, Yan H. Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. Thromb Res. 2017;154:96–105.

    Article  CAS  PubMed  Google Scholar 

  68. Rubin O, Crettaz D, Canellini G, Tissot JD, Lion N. Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. Vox Sang. 2008;95(4):288–97.

    Article  CAS  PubMed  Google Scholar 

  69. Liu C, Zhao W, Christ GJ, Gladwin MT, Kim-Shapiro DB. Nitric oxide scavenging by red cell microparticles. Free Radic Biol Med. 2013;65:1164–73.

    Article  CAS  PubMed  Google Scholar 

  70. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124(4):465–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, et al. Human neuroglobin functions as a redox-regulated nitrite reductase. J Biol Chem. 2011;286(20):18277–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Liu Y, Zhang R, Qu H, Wu J, Li L, Tang Y. Endothelial microparticles activate endothelial cells to facilitate the inflammatory response. Mol Med Rep. 2017;15(3):1291–6.

    Article  CAS  PubMed  Google Scholar 

  73. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, et al. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood. 2011;118(8):2366–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bardelli C, Amoruso A, Federici Canova D, Fresu L, Balbo P, Neri T, et al. Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands. Br J Pharmacol. 2012;165(3):716–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Mastronardi ML, Mostefai HA, Soleti R, Agouni A, Martínez MC, Andriantsitohaina R. Microparticles from apoptotic monocytes enhance nitrosative stress in human endothelial cells. Fundam Clin Pharmacol. 2011;25(6):653–60.

    Article  CAS  PubMed  Google Scholar 

  76. Lee SK, Yang SH, Kwon I, Lee OH, Heo JH. Role of tumour necrosis factor receptor-1 and nuclear factor-κB in production of TNF-α-induced pro-inflammatory microparticles in endothelial cells. Thromb Haemost. 2014;112(3):580–8.

    Article  CAS  PubMed  Google Scholar 

  77. Jansen F, Yang X, Franklin BS, Hoelscher M, Schmitz T, Bedorf J, et al. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res. 2013;98(1):94–106.

    Article  CAS  PubMed  Google Scholar 

  78. Taguchi K, Hida M, Narimatsu H, Matsumoto T, Kobayashi T. Glucose and angiotensin II-derived endothelial extracellular vesicles regulate endothelial dysfunction via ERK1/2 activation. Pflugers Arch. 2017;469(2):293–302.

    Article  CAS  PubMed  Google Scholar 

  79. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81.

    Article  PubMed  Google Scholar 

  80. Jansen F, Yang X, Baumann K, Przybilla D, Schmitz T, Flender A, et al. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med. 2015;19(9):2202–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Osman A, El-Gamal H, Pasha M, Zeidan A, Korashy HM, Abdelsalam SS, et al. Endoplasmic reticulum (ER) stress-generated extracellular vesicles (microparticles) self-perpetuate ER stress and mediate endothelial cell dysfunction independently of cell survival. Front Cardiovasc Med. 2020;7:584791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Dasgupta SK, Abdel-Monem H, Niravath P, Le A, Bellera RV, Langlois K, et al. Lactadherin and clearance of platelet-derived microvesicles. Blood. 2009;113(6):1332–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6(9):1517–24.

    Article  CAS  PubMed  Google Scholar 

  84. Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007;115(16):2168–77.

    Article  CAS  PubMed  Google Scholar 

  85. Khandagale A, Corcoran P, Nikpour M, Isaksson A, Wikström G, Siegbahn A, et al. MircoRNA in extracellular vesicles from patients with pulmonary arterial hypertension alters endothelial angiogenic response. Int J Mol Sci. 2022;23(19):11964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Khandagale A, Åberg M, Wikström G, Bergström Lind S, Shevchenko G, Björklund E, et al. Role of extracellular vesicles in pulmonary arterial hypertension: modulation of pulmonary endothelial function and angiogenesis. Arterioscler Thromb Vasc Biol. 2020;40(9):2293–309.

    Article  CAS  PubMed  Google Scholar 

  87. Amabile N, Heiss C, Chang V, Angeli FS, Damon L, Rame EJ, et al. Increased CD62e+ endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transpl. 2009;28(10):1081–6.

    Article  Google Scholar 

  88. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177(5):536–43.

    Article  CAS  PubMed  Google Scholar 

  89. Belik D, Tsang H, Wharton J, Howard L, Bernabeu C, Wojciak-Stothard B. Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesis. J Biomed Sci. 2016;23:4.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Diehl P, Aleker M, Helbing T, Sossong V, Germann M, Sorichter S, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis. 2011;31(2):173–9.

    Article  PubMed  Google Scholar 

  91. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med. 2008;177(11):1268–75.

    Article  CAS  PubMed  Google Scholar 

  92. Amabile N, Guignabert C, Montani D, Yeghiazarians Y, Boulanger CM, Humbert M. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J. 2013;42(1):272–9.

    Article  CAS  PubMed  Google Scholar 

  93. Aliotta JM, Pereira M, Amaral A, Sorokina A, Igbinoba Z, Hasslinger A, et al. Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice. Cardiovasc Res. 2013;100(3):354–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016;110(3):319–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Blair LA, Haven AK, Bauer NN. Circulating microparticles in severe pulmonary arterial hypertension increase intercellular adhesion molecule-1 expression selectively in pulmonary artery endothelium. Respir Res. 2016;17(1):133.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Stevens T. Functional and molecular heterogeneity of pulmonary endothelial cells. Proc Am Thorac Soc. 2011;8(6):453–7.

    Article  CAS  PubMed  Google Scholar 

  97. Fujimoto S, Fujita Y, Kadota T, Araya J, Kuwano K. Intercellular communication by vascular endothelial cell-derived extracellular vesicles and vheir vicroRNAs in respiratory diseases. Front Mol Biosci. 2021;7:619697.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Tual-Chalot S, Guibert C, Muller B, Savineau JP, Andriantsitohaina R, Martinez MC. Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction. Am J Respir Crit Care Med. 2010;182(2):261–8.

    Article  CAS  PubMed  Google Scholar 

  99. Zhao L, Luo H, Li X, Li T, He J, Qi Q, et al. Exosomes derived from human pulmonary artery endothelial cells shift the balance between proliferation and apoptosis of smooth muscle cells. Cardiology. 2017;137(1):43–53.

    Article  CAS  PubMed  Google Scholar 

  100. Chen T, Sun MR, Zhou Q, Guzman AM, Ramchandran R, Chen J, et al. Extracellular vesicles derived from endothelial cells in hypoxia contribute to pulmonary artery smooth muscle cell proliferation in-vitro and pulmonary hypertension in mice. Pulm Circ. 2022;12(1):e12014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Su Y, Tan R, Sun M, Yuan L, Ruiz M, Dupuis J, et al. MiR-1249 on endothelial extracellular vesicles mediates cigarette smoke-induced pulmonary hypertension by inhibiting HDAC10 (histone deacetylase 10)-NFκB (nuclear factor κB)-CaSR (calcium-sensing receptor) cascade. Hypertension. 2022;79(12):2721–32.

    Article  CAS  PubMed  Google Scholar 

  102. Zhu L, Xiao R, Zhang X, Lang Y, Liu F, Yu Z, et al. Spermine on endothelial extracellular vesicles mediates smoking-induced pulmonary hypertension partially through calcium-sensing receptor. Arterioscler Thromb Vasc Biol. 2019;39(3):482–95.

    Article  CAS  PubMed  Google Scholar 

  103. Gu J, Zhang H, Ji B, Jiang H, Zhao T, Jiang R, et al. Vesicle miR-195 derived from endothelial cells inhibits expression of serotonin transporter in vessel smooth muscle cells. Sci Rep. 2017;7:43546.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Sindi HA, Russomanno G, Satta S, Abdul-Salam VB, Jo KB, Qazi-Chaudhry B, et al. Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat Commun. 2020;11(1):1185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14(3):249–56.

    Article  CAS  PubMed  Google Scholar 

  106. Zheng B, Yin WN, Suzuki T, Zhang XH, Zhang Y, Song LL, et al. Exosome-mediated miR-155 transfer from smooth muscle cells to endothelial cells induces endothelial injury and promotes atherosclerosis. Mol Ther. 2017;25(6):1279–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. de la Cuesta F, Passalacqua I, Rodor J, Bhushan R, Denby L, Baker AH. Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-β signalling: implications for PAH vascular remodelling. Cell Commun Signal. 2019;17(1):143.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Li L, Wang Z, Hu X, Wan T, Wu H, Jiang W, et al. Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2016;479(2):343–50.

    Article  CAS  PubMed  Google Scholar 

  109. Deng L, Blanco FJ, Stevens H, Lu R, Caudrillier A, McBride M, et al. MicroRNA-143 activation regulates smooth muscle and cndothelial cell crosstalk in pulmonary arterial hypertension. Circ Res. 2015;117(10):870–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Vajen T, Benedikter BJ, Heinzmann ACA, Vasina EM, Henskens Y, Parsons M, et al. Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. J Extracell Vesicles. 2017;6(1):1322454.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Akhmedov A, Sawamura T, Chen CH, Kraler S, Vdovenko D, Lüscher TF. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J. 2021;42(18):1797–807.

    Article  CAS  PubMed  Google Scholar 

  112. Huang N, Wang D, Zhu TT, Ge XY, Liu H, Yao MZ, et al. Plasma exosomes confer hypoxic pulmonary hypertension by transferring LOX-1 cargo to trigger phenotypic switching of pulmonary artery smooth muscle cells. Biochem Pharmacol. 2023;207:115350.

    Article  CAS  PubMed  Google Scholar 

  113. Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS ONE. 2009;4(9):e7140.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Sharma H, Chinnappan M, Agarwal S, Dalvi P, Gunewardena S, O’Brien-Ladner A, et al. Macrophage-derived extracellular vesicles mediate smooth muscle hyperplasia: role of altered miRNA cargo in response to HIV infection and substance abuse. FASEB J. 2018;32(9):5174–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013;132(2):180–4.

    Article  CAS  PubMed  Google Scholar 

  116. Hernández C, Orbe J, Roncal C, Alvarez-Hernandez M, Martinez de Lizarrondo S, Alves MT, et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost. 2013;110(3):598–608.

    Article  PubMed  Google Scholar 

  117. Sartori MT, Della Puppa A, Ballin A, Campello E, Radu CM, Saggiorato G, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost. 2013;110(2):378–85.

    CAS  PubMed  Google Scholar 

  118. Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res. 2014;134(5):1093–6.

    Article  CAS  PubMed  Google Scholar 

  119. Fricke A, Ullrich PV, Cimniak AFV, Becherer C, Follo M, Heinz J, et al. Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer. 2017;17(1):527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Sánchez-López V, Gao L, Ferrer-Galván M, Arellano-Orden E, Elías-Hernández T, Jara-Palomares L, et al. Differential biomarker profiles between unprovoked venous thromboembolism and cancer. Ann Med. 2020;52(6):310–20.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Signorelli SS, Oliveri Conti G, Fiore M, Cangiano F, Zuccarello P, Gaudio A, et al. Platelet-derived microparticles (MPs) and thrombin generation velocity in deep vein thrombosis (DVT): results of a case-control study. Vasc Health Risk Manag. 2020;16:489–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Melnichnikova O, Zhilenkova Y, Sirotkina O, Zolotova E, Pishchulov K, Tastanbekov M, et al. Circulating small extracellular vesicles profiling and thrombin generation as potential markers of thrombotic risk in glioma patients. Front Cardiovasc Med. 2022;9:789937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Zang X, Su Y, Zhang W, Cao X, Li C, Lu S, et al. Hepatocyte-derived microparticles as novel biomarkers for the diagnosis of deep venous thrombosis in trauma patients. Clin Appl Thromb Hemost. 2023;29:10760296231153400.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Akinnusi ME, El Solh AA. Circulating endothelial microparticle levels and hemodynamic severity of pulmonary hypertension: is there a role for sleep apnea? Am J Respir Crit Care Med. 2009;179(4):328 (author reply 328–9).

    Article  PubMed  Google Scholar 

  125. Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, et al. Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol. 2010;31(5):657–62.

    Article  PubMed  Google Scholar 

  126. Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, Pinsky DJ. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS ONE. 2012;7(7):e40829.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Nadaud S, Poirier O, Girerd B, Blanc C, Montani D, Eyries M, et al. Small platelet microparticle levels are increased in pulmonary arterial hypertension. Eur J Clin Invest. 2013;43(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  128. Rose JA, Wanner N, Cheong HI, Queisser K, Barrett P, Park M, et al. Flow cytometric quantification of peripheral blood cell β-adrenergic receptor density and urinary endothelial cell-derived microparticles in pulmonary arterial hypertension. PLoS ONE. 2016;11(6):e0156940.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Lammi MR, Saketkoo LA, Okpechi SC, Ghonim MA, Wyczechowska D, Bauer N, et al. Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers. Respirology. 2019;24(7):675–83.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Ogawa A, Matsubara H. Increased levels of platelet-derived microparticles in pulmonary hypertension. Thromb Res. 2020;195:120–4.

    Article  CAS  PubMed  Google Scholar 

  131. Tura-Ceide O, Blanco I, Garcia-Lucio J, Del Pozo R, García AR, Ferrer E, et al. Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response. Cells. 2021;10(7):1688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Li WD, Li XQ. Endothelial progenitor cells accelerate the resolution of deep vein thrombosis. Vascul Pharmacol. 2016;83:10–6.

    Article  CAS  PubMed  Google Scholar 

  133. Meng Q, Wang W, Yu X, Li W, Kong L, Qian A, et al. Upregulation of MicroRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem. 2015;116(8):1613–23.

    Article  CAS  PubMed  Google Scholar 

  134. Sun J, Zhang Z, Ma T, Yang Z, Zhang J, Liu X, et al. Endothelial progenitor cell-derived exosomes, loaded with miR-126, promoted deep vein thrombosis resolution and recanalization. Stem Cell Res Ther. 2018;9(1):223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Chen JY, An R, Liu ZJ, Wang JJ, Chen SZ, Hong MM, et al. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol Sin. 2014;35:1121–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016;110:319–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Hogan SE, Rodriguez Salazar MP, Cheadle J, Glenn R, Medrano C, Petersen TH, et al. Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2019;316:L723–37.

    Article  CAS  PubMed  Google Scholar 

  138. Aliotta JM, Pereira M, Wen S, Dooner MS, Del Tatto M, Papa E, et al. Bone marrow endothelial progenitor cells are the cellular mediators of pulmonary hypertension in the murine monocrotaline injury model. Stem Cells Transl Med. 2017;6:1595–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

JZ, Ph.D., is an investigator in Tongji Medical College; XH, MD, is an investigator in Shanghai Pulmonary Hospital; TW, MD and Ph.D., is a professor in Tongji Medical College; RX, Ph.D., is a lecturer in Tongji Medical College; LZ, MD and Ph.D., is a professor in Tongji Medical College; MR, Ph.D., is a professor in Université de Montréal; JD, MD., is a professor in Université de Montréal; QH, MD and Ph.D., is a professor in Tongji Medical College.

Funding

This study was supported by grants from the National Natural Science Foundation of China (82241014, 82130002, 82325001, 82170068 and 82270060).

Author information

Author notes

  1. Jiwei Zhang, Xiaoyi Hu and Tao Wang equal contributors.

Authors and Affiliations

  1. Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China

    Jiwei Zhang, Xiaoyi Hu, Rui Xiao, Liping Zhu & Qinghua Hu

  2. Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China

    Jiwei Zhang, Xiaoyi Hu, Rui Xiao, Liping Zhu & Qinghua Hu

  3. Department of Pathology, Union Hospital, Tongji Medical College, HUST, Wuhan, China

    Jiwei Zhang

  4. Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    Xiaoyi Hu

  5. Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, HUST, Wuhan, China

    Tao Wang

  6. Department of Nutrition, Université de Montréal, Montreal, Canada

    Matthieu Ruiz

  7. Montreal Heart Institute, Montréal, Québec, Canada

    Matthieu Ruiz & Jocelyn Dupuis

  8. Department of Medicine, Université de Montréal, Montréal, Québec, Canada

    Jocelyn Dupuis

Authors
  1. Jiwei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoyi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liping Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matthieu Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jocelyn Dupuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qinghua Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QH initiated the study and hypothesis, QH, JZ, XH and TW drafted the manuscript, QH, RX, LZ, MR and JD revised the manuscript, QH finalized the work, all authors approved its submission.

Corresponding author

Correspondence to Qinghua Hu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors approved its publication.

Competing interests

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., Hu, X., Wang, T. et al. Extracellular vesicles in venous thromboembolism and pulmonary hypertension. J Nanobiotechnol 21, 461 (2023). https://doi.org/10.1186/s12951-023-02216-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12951-023-02216-3

Keywords

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us